KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Other Non-Current Liabilities (2020 - 2025)

AbCellera Biologics (ABCL) has disclosed Other Non-Current Liabilities for 6 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Liabilities fell 9.06% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Sep 2025, down 9.06%, and an annual FY2024 reading of $7.2 million, up 21.39% over the prior year.
  • Other Non-Current Liabilities was $1.4 million for Q3 2025 at AbCellera Biologics, down from $1.6 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $24.6 million in Q2 2022 and bottomed at $1.4 million in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $6.3 million, with a median of $5.1 million recorded in 2023.
  • The sharpest move saw Other Non-Current Liabilities plummeted 81.06% in 2021, then surged 1386.36% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $1.7 million in 2021, then soared by 826.37% to $16.1 million in 2022, then tumbled by 63.21% to $5.9 million in 2023, then increased by 21.39% to $7.2 million in 2024, then plummeted by 80.67% to $1.4 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ABCL at $1.4 million in Q3 2025, $1.6 million in Q2 2025, and $1.6 million in Q1 2025.